Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance (scientific article published on 8 November 2011)

cites work (P2860)

Q39251464	A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms.
Q64057568	A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Q48118338	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
Q36889620	A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
Q64103643	A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
Q90746260	A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer
Q50884294	ABCB6 RNA expression in leukemias--expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia.
Q38850586	ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.
Q39005733	ATP-binding casette transporter expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers.
Q36334681	Advantages of the avian model for human ovarian cancer
Q64904197	An Organoid-Based Preclinical Model of Human Gastric Cancer.
Q39308117	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors
Q38704070	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Q35196335	Assessment of cancer cell line representativeness using microarrays for Merkel cell carcinoma
Q37236624	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.
Q99413493	BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Q40179397	Barriers to generating PDX models of HPV-related head and neck cancer.
Q37338293	Beyond 3D culture models of cancer
Q37238101	Beyond PSA: the next generation of prostate cancer biomarkers
Q92159343	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs
Q90385469	Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine
Q59183001	Biodistribution and Pharmacokinetic Evaluations of a Novel Taxoid DHA-SBT-1214 in an Oil-in-Water Nanoemulsion Formulation in Naïve and Tumor-Bearing Mice
Q26770495	Bioengineering Models for Breast Cancer Research
Q92757507	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
Q35817482	CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid
Q92503481	CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs
Q26800337	Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
Q36037500	Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?
Q36105474	Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes
Q90620231	Clinical Implementation of Precision Medicine in Gastric Cancer
Q52576433	Comparative High-Resolution Transcriptome Sequencing of Lymphoma Cell Lines and de novo Lymphomas Reveals Cell-Line-Specific Pathway Dysregulation.
Q64083322	Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines
Q38765553	Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line
Q38904995	Computational models for predicting drug responses in cancer research
Q37676502	Culture models to define key mediators of cancer matrix remodeling
Q92493643	Current Applications of Nanoemulsions in Cancer Therapeutics
Q27028117	Current status and evolution of preclinical drug development models of epithelial ovarian cancer
Q36502676	De-escalation of radiation dose for human papillomavirus-positive oropharyngeal head and neck squamous cell carcinoma: A case report and preclinical and clinical literature review
Q42428131	Deciphering the Correlation between Breast Tumor Samples and Cell Lines by Integrating Copy Number Changes and Gene Expression Profiles
Q38749141	Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
Q99237685	Developing preclinical models of neuroblastoma: driving therapeutic testing
Q36637164	Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts
Q38869271	Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Q96610114	Discovering and validating cancer genetic dependencies: approaches and pitfalls
Q91468454	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas
Q92377454	Editor's inaugural issue foreword: perspectives on translational and clinical research
Q45854382	Effect of X-ray irradiation on expression of organic anion transporting polypeptides
Q36266655	Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.
Q99616642	Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Q28588419	Efficient and simple approach to in vitro culture of primary epithelial cancer cells
Q34364604	Entry tropism of BK and Merkel cell polyomaviruses in cell culture
Q50976501	Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells.
Q47137308	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
Q35974087	Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines
Q47153374	Establishment and Characterization of Primary Cultures from Iranian Oral Squamous Cell Carcinoma Patients by Enzymatic Method and Explant Culture
Q88913296	Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone
Q47140693	Establishment and evaluation of four different types of patient-derived xenograft models
Q92092492	Establishment of hepatocellular carcinoma patient-derived xenografts from image-guided percutaneous biopsies
Q28539620	Establishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cells
Q41158938	Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness.
Q64054816	Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data
Q37025950	Evaluating cell lines as tumour models by comparison of genomic profiles
Q38704362	Evaluating hepatocellular carcinoma cell lines for tumour samples using within-sample relative expression orderings of genes.
Q38753542	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
Q35909089	Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.
Q96303379	Feature selection strategies for drug sensitivity prediction
Q47873443	From Classical Toxicology to Tox21: Some Critical Conceptual and Technological Advances in the Molecular Understanding of the Toxic Response Beginning From the Last Quarter of the 20th Century
Q48747209	Functional Genomic Characterization of Cancer Genomes
Q37624039	GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report
Q36502518	Genetic heterogeneity of RPMI-8402, a T-acute lymphoblastic leukemia cell line
Q50083199	Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies
Q33555287	Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Q91996454	HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models
Q38957511	Heralding a new paradigm in 3D tumor modeling
Q36472233	Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma
Q31018677	How Consistent are Publicly Reported Cytotoxicity Data? Large-Scale Statistical Analysis of the Concordance of Public Independent Cytotoxicity Measurements
Q33894635	Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening
Q37269137	Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.
Q36562337	Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues
Q36456104	Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors
Q36310845	In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer
Q33648440	Individual patient oesophageal cancer 3D models for tailored treatment
Q30791224	Inference and validation of predictive gene networks from biomedical literature and gene expression data
Q27321370	Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts
Q28486233	Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved
Q96127021	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts
Q38001734	Investigational ABC transporter inhibitors
Q49335222	Loperamide, an antidiarrheal agent, induces apoptosis and DNA damage in leukemia cells
Q30841262	Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer
Q92932414	Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma
Q46291182	Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Q92131580	Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways
Q37110909	Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes
Q46928031	Microencapsulation of low-passage poorly-differentiated human mucoepidermoid carcinoma cells by alginate microcapsules: in vitro profiling of angiogenesis-related molecules.
Q37137850	Microfabricated polymeric vessel mimetics for 3-D cancer cell culture
Q33641924	Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems
Q26786724	Molecular and clinical implementations of ovarian cancer mouse avatar models
Q39112194	Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing
Q37190124	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment
Q35618225	Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
Q39590420	Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy
Q47929908	Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.
Q38616847	Natural Products That Target Cancer Stem Cells
Q40406145	New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis.
Q36094989	New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.
Q52430564	New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Q90598312	Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines
Q92101442	Optical detection of the structural properties of tumor tissue generated by xenografting of drug-sensitive and drug-resistant cancer cells using partial wave spectroscopy (PWS)
Q31134293	Optimization of cell lines as tumour models by integrating multi-omics data.
Q49484270	Osteosarcoma: Accelerating Progress Makes for a Hopeful Future
Q38749909	Overview of the Use of Murine Models in Leukemia and Lymphoma Research.
Q55438732	PATIENT-DERIVED XENOGRAFTS AS A PRECLINICAL MODEL FOR BONE SARCOMAS.
Q36413247	Patient-derived cell models as preclinical tools for genome-directed targeted therapy
Q39057246	Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Q52311090	Patient-derived xenograft models in musculoskeletal malignancies.
Q27026531	Patient-derived xenograft models of breast cancer and their predictive power
Q34205518	Patient-derived xenograft models: an emerging platform for translational cancer research
Q50027944	Patient-derived xenografts as preclinical neuroblastoma models
Q40416521	Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation
Q92707813	Photoacoustic imaging of cells in a three-dimensional microenvironment
Q92960597	Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro
Q43833882	Possible paths and potential barriers to successfully modeling drug resistance
Q33626025	Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.
Q50096902	Preclinical mouse solid tumour models: status quo, challenges and perspectives.
Q57811412	Predicting Tumor Sensitivity to Chemotherapeutic Drugs in Oral Squamous Cell Carcinoma Patients
Q35212386	Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Q47103226	Profiles of a broad spectrum of epigenetic DNA modifications in normal and malignant human cell lines: Proliferation rate is not the major factor responsible for the 5-hydroxymethyl-2'-deoxycytidine level in cultured cancerous cell lines
Q55603677	Proposed Molecular and miRNA Classification of Gastric Cancer.
Q28533786	Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24
Q44392303	Radiosensitization of brain metastasis by targeting c-MET.
Q35101229	Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems
Q38741073	Recently identified drug resistance biomarkers in ovarian cancer
Q36283038	Recurrent oral cancer: current and emerging therapeutic approaches.
Q40114886	Revisiting the concept of a cytopathic viral infection.
Q64057258	Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts
Q50892020	SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
Q89453574	SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Q64106463	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system
Q37164553	Short-form Ron is a novel determinant of ovarian cancer initiation and progression
Q41633592	Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine
Q92073945	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening
Q36234042	Targeting of Rac GTPases blocks the spread of intact human breast cancer.
Q42322516	Targeting of phage particles towards endothelial cells by antibodies selected through a multi-parameter selection strategy.
Q33763765	Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance
Q38263008	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
Q26829581	Technologies for deriving primary tumor cells for use in personalized cancer therapy
Q57461609	The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death
Q28681646	The Merkel cell polyomavirus minor capsid protein
Q37526352	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Q34025933	The RPTEC/TERT1 cell line models key renal cell responses to the environmental toxicants, benzo[a]pyrene and cadmium
Q98154733	The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features
Q36812960	The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene
Q92442405	The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
Q36953572	The clinical relevance of cancer cell lines.
Q90355865	The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers
Q49611544	The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.
Q40389670	The functional consequences and prognostic value of dosage sensitivity in ovarian cancer
Q55260441	The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Q38085500	The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
Q47655442	Tissue specificity of in vitro drug sensitivity.
Q92013746	Traditional and Advanced Cell Cultures in Hematopoietic Stem Cell Studies
Q35000404	U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells
Q36288376	Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups
Q38773990	Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models.
Q41706958	Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.
Q35602135	Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies
Q38726177	ZFP91: A Noncanonical NF-κB Signaling Pathway Regulator with Oncogenic Properties Is Overexpressed in Prostate Cancer

P819	ADS bibcode	2011PNAS..10818708G
P356	DOI	10.1073/PNAS.1111840108
P932	PMC publication ID	3219108
P698	PubMed publication ID	22068913
P5875	ResearchGate publication ID	51784713

P50	author	Michael M. Gottesman	Q6832389
		Sudhir Varma	Q42564591
		Anna M. Calcagno	Q42718489
		Anil K. Sood	Q88114757
P2093	author name string	Miguel Marino
		Bo R Rueda
		Jean-Pierre Gillet
		Suresh V Ambudkar
		Ben Davidson
		Ram Ganapathi
		Josiah N Orina
		Chirayu Patel
		Vineet Singal
		Lisa J Green
		Raji Padmanabhan
		Tatiana A Eliseeva
		Meena I Vora
P2860	cites work	Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.	Q42445479
		Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines	Q42814149
		Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins.	Q42816887
		BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy	Q43606278
		Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines	Q44605132
		Apoptotic pathways of epothilone BMS 310705	Q44608420
		Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation	Q46921232
		Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient.	Q52833988
		Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia	Q58597512
		How accurate are cancer cell lines?	Q59088382
		Mechanisms of multidrug resistance in cancer	Q84966118
		A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes	Q24647928
		Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer	Q27694658
		Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling	Q27860529
		The NCI60 human tumour cell line anticancer drug screen	Q29614975
		Targeting multidrug resistance in cancer	Q29616803
		Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy	Q29617584
		A gene expression database for the molecular pharmacology of cancer	Q29619242
		ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia	Q33251273
		The biology of ovarian cancer: new opportunities for translation	Q33622369
		Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array	Q33828375
		Chemosensitivity prediction by transcriptional profiling	Q33943845
		Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics	Q34267466
		A global map of human gene expression	Q34280845
		Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.	Q35575176
		Molecular concepts analysis links tumors, pathways, mechanisms, and drugs	Q35812701
		Models of ovarian cancer--are we there yet?	Q36162833
		DualChip microarray as a new tool in cancer research	Q36481097
		Microarray analysis and tumor classification	Q36499716
		Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability	Q36614811
		Chemotherapy-induced resistance by ATP-binding cassette transporter genes.	Q36850578
		Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility	Q37106813
		Gene-expression profiling in epithelial ovarian cancer	Q37224303
		A complex barcode underlies the heterogeneous response of p53 to stress	Q37249372
		Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database	Q37330648
		Cytoplasmic functions of the tumour suppressor p53.	Q37466228
		Animal models of ovarian cancer	Q37599439
		Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents	Q37714306
		Molecular characterization of ovarian cancer by gene-expression profiling.	Q37741508
		Transcriptional regulation by p53.	Q37777267
		Do predictive signatures really predict response to cancer chemotherapy?	Q37819795
		Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration	Q38291182
		Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes	Q38333027
		Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells	Q38337454
		ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug	Q39780753
P433	issue	46
P407	language of work or name	English	Q1860
P304	page(s)	18708-18713
P577	publication date	2011-11-08
P1433	published in	Proceedings of the National Academy of Sciences of the United States of America	Q1146531
P1476	title	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
P478	volume	108

Q54604950	786-O
Q54606041	A-498
Q4649475	A-549
Q54608371	ACHN
Q54798471	BT-549
Q54809015	CCRF-CEM
Q54814074	COLO 205
Q54808374	Caki-1
Q5206280	DU145
Q54832197	EKVX
Q54881683	HCC2998
Q28334584	HCT 116
Q54882006	HCT 15
Q5630035	HL-60
Q54890155	HOP-62
Q54890156	HOP-92
Q28334700	HT-29
Q54895774	Hs 578T
Q54897382	IGROV-1
Q6324626	K-562
Q54900052	KM12
Q38098914	Kasumi-1
Q54902908	LOX-IMVI
Q51838638	M14
Q1881253	MCF-7
Q17577870	MDA-MB-231
Q50952937	MDA-MB-435
Q54906365	MOLT-4
Q54903981	Malme-3M
Q54907717	NCI-ADR-RES
Q54907948	NCI-H226
Q54907958	NCI-H23
Q54908034	NCI-H322M
Q54908057	NCI-H460
Q54908074	NCI-H522
Q54937005	OVCAR-3
Q54937010	OVCAR-4
Q54937011	OVCAR-5
Q54937014	OVCAR-8
Q7118483	PC-3
Q54951245	RPMI-8226
Q54951507	RXF 393L
Q54952917	SF268
Q54952919	SF295
Q54952931	SF539
Q54953905	SK-MEL-2
Q54954013	SK-MEL-28
Q54954250	SK-MEL-5
Q50432263	SK-OV-3
Q54955018	SN12C
Q54955038	SNB-19
Q54955042	SNB-75
Q54955622	SR
Q28519412	SW620
Q54971341	T-47D
Q54972524	TK-10
Q54973550	U-251MG
Q54973827	UACC-257
Q54973858	UACC-62
Q54991243	UO-31

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance

scientific article published on 8 November 2011

Reverse relations